Free Trial

Sight Sciences Q3 2024 Earnings Report

Sight Sciences logo
$2.83 -0.01 (-0.35%)
As of 01/17/2025 04:00 PM Eastern

Sight Sciences EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Sight Sciences Revenue Results

Actual Revenue
$20.16 million
Expected Revenue
$20.41 million
Beat/Miss
Missed by -$250.00 thousand
YoY Revenue Growth
N/A

Sight Sciences Announcement Details

Quarter
Q3 2024
Time
N/A

Sight Sciences Earnings Headlines

Citi Remains a Hold on Sight Sciences (SGHT)
Sight Sciences price target lowered to $3 from $5 at Lake Street
Tesla Shares Soar After Trump Win (Act Now)
Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.
Sight Sciences (SGHT) Receives a Hold from Needham
See More Sight Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email.

About Sight Sciences

Sight Sciences (NASDAQ:SGHT), an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

View Sight Sciences Profile

More Earnings Resources from MarketBeat